

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



北京市春立正達醫療器械股份有限公司

**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1858)**

## **2026 THIRD QUARTERLY REPORT**

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**Third Quarterly Report**”) of the Group for the nine months ended 30 September 2026 are provided. The financial information contained in the Third Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises (“**CASs**”), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The Third Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the Third Quarterly Report shall prevail.

By order of the Board

**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

**Shi Wenling**

*Chairman*

Beijing, the PRC, 30 October 2026

*As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Kwan King Nam and Mr. Zheng Zhong Liang.*

\* For identification purposes only

## **Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

### **2026 Third Quarterly Report**

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

#### **IMPORTANT NOTICE:**

The Board of Directors of the Company, the Directors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge of accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the third quarter are audited

☐ Yes   ☒ No

# 1. KEY FINANCIAL DATA

## (A) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

| Items                                                                                                          | Current Reporting Period | Percentage change of the Current Reporting Period as compared to the corresponding period of last year (%) | From the beginning of the year to the end of the Reporting Period | Percentage change from the beginning of the year to the end of Reporting Period compared to the corresponding period of last year (%) |
|----------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Revenue                                                                                                        | 209,372,895.26           | -22.02                                                                                                     | 626,477,112.40                                                    | -17.14                                                                                                                                |
| Gross profit                                                                                                   | 79,029,589.08            | -6.45                                                                                                      | 212,486,833.21                                                    | 0.33                                                                                                                                  |
| Net profit attributable to the shareholders of the listed company                                              | 68,600,507.93            | -10.98                                                                                                     | 188,557,525.99                                                    | -1.55                                                                                                                                 |
| Net profit attributable to the shareholders of the listed company after deducting non-recurring profit or loss | 66,985,049.17            | -10.11                                                                                                     | 181,132,677.63                                                    | 0.24                                                                                                                                  |
| Net cash flow from operating activities                                                                        | N/A                      | N/A                                                                                                        | 117,514,412.55                                                    | -32.68                                                                                                                                |
| Basic earnings per share (RMB/share)                                                                           | 0.18                     | -10.00                                                                                                     | 0.49                                                              | -2.00                                                                                                                                 |
| Diluted earnings per share (RMB/share)                                                                         | 0.18                     | -10.00                                                                                                     | 0.49                                                              | -2.00                                                                                                                                 |
| Weighted average RONA (%)                                                                                      | 2.22                     | Decrease by 0.40 percentage points                                                                         | 6.17                                                              | Decrease by 0.43 percentage points                                                                                                    |
| Total investments in research and development                                                                  | 22,738,546.54            | -36.16                                                                                                     | 69,965,203.25                                                     | -19.09                                                                                                                                |
| Percentage of research and development investment to revenue (%)                                               | 10.86                    | Decrease by 2.41 percentage points                                                                         | 11.17                                                             | Decrease by 0.27 percentage points                                                                                                    |
|                                                                                                                |                          | At the end of the Reporting Period                                                                         | At the end of last year                                           | Percentage change at the end of the Reporting Period as compared to the end of last year (%)                                          |
| Total assets                                                                                                   | 3,648,631,599.65         |                                                                                                            | 3,661,134,861.13                                                  | -0.34                                                                                                                                 |
| Owners' equity attributable to the shareholders of the listed company                                          | 3,116,696,614.79         |                                                                                                            | 2,985,467,836.15                                                  | 4.40                                                                                                                                  |

Note: The "Reporting Period" refers to the three-month period from the beginning to the end of the current quarter as the same below.

# 1. KEY FINANCIAL DATA (CONTINUED)

## (B) Non-recurring profit or loss items and amounts

✓Applicable    □Non applicable

| <i>Unit: Yuan    Currency: RMB</i>                                                                                                                                                                                                                                                                                                          |                                  |                                                                  |             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------|-------------|
| Non-recurring gain or loss item                                                                                                                                                                                                                                                                                                             | Amount for the<br>current period | Amount from<br>the beginning of<br>the year to the<br>end of the | Description |
|                                                                                                                                                                                                                                                                                                                                             |                                  | Reporting Period                                                 |             |
| Gain and loss from disposal of non-current assets, including write-off of provision for asset impairment                                                                                                                                                                                                                                    |                                  | 47,000.94                                                        |             |
| Government grants included in profit or loss for the current period, excluding government grants that are closely related to the normal operation of the Company, complying with the requirements of national policy, entitled as per the standard established, and those that have continuous effect to the profit and loss of the Company | 179,988.12                       | 2,091,716.12                                                     |             |
| Except for effective hedging business conducted in the ordinary course of business of the Company, gain or loss arising from change in fair value of financial assets held by and financial liabilities arising from non-financial enterprises, and gain or loss arising from disposal of financial assets and financial liabilities        | 1,766,308.22                     | 8,232,863.02                                                     |             |
| Capital utilization fee received from non-financial enterprises included in current gain or loss                                                                                                                                                                                                                                            |                                  |                                                                  |             |
| Gain or loss on entrusted investments or assets under management                                                                                                                                                                                                                                                                            |                                  |                                                                  |             |
| Gain or loss on entrusted loans                                                                                                                                                                                                                                                                                                             |                                  |                                                                  |             |
| Loss on assets due to force majeure events, such as natural disasters                                                                                                                                                                                                                                                                       |                                  |                                                                  |             |
| Reversal of the impairment provision for receivables under independent impairment test                                                                                                                                                                                                                                                      |                                  |                                                                  |             |
| Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of identifiable net assets of the investees at the time of acquisition                                                                                                                                       |                                  |                                                                  |             |
| Net gain or loss of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control                                                                                                                                                              |                                  |                                                                  |             |

## 1. KEY FINANCIAL DATA (CONTINUED)

### (B) Non-recurring profit or loss items and amounts (continued)

| Non-recurring gain or loss item                                                                                                                | Amount for the<br>current period | Amount from<br>the beginning of<br>the year to the<br>end of the<br>Reporting Period | Description |
|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------|-------------|
| Gain or loss on exchange of non-monetary assets                                                                                                |                                  |                                                                                      |             |
| Gain or loss on debt restructuring                                                                                                             |                                  |                                                                                      |             |
| One-off expenses incurred by enterprises due to the discontinuity of relevant business activities, such as staff resettlement expenses         |                                  |                                                                                      |             |
| One-off effect on current profit or loss due to the adjustments to laws and regulations on tax and accounting                                  |                                  |                                                                                      |             |
| One-off share-based payment expenses recognised due to cancellation and modification of share incentive scheme                                 |                                  |                                                                                      |             |
| Gain or loss arising from changes in the fair value of employee benefits for cash-settled share-based payments, payable after the vesting date |                                  |                                                                                      |             |
| Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement                     |                                  |                                                                                      |             |
| Gain on transactions at unfair trading prices                                                                                                  |                                  |                                                                                      |             |
| Gain or loss from other contingencies which are not related to the Company's normal operations                                                 |                                  |                                                                                      |             |
| Custody fee income from custody operations                                                                                                     |                                  |                                                                                      |             |
| Other non-operating income and expenses other than aforesaid items                                                                             | 277,166.61                       | -1,402,249.97                                                                        |             |
| Other gain or loss items within the definition of non-recurring profit or loss                                                                 | -321,729.44                      | -176,407.30                                                                          |             |
| Less: Impact of income tax                                                                                                                     | 285,854.75                       | 1,367,211.85                                                                         |             |
| Effect of minority interests (after tax)                                                                                                       | 420                              | 862.60                                                                               |             |
| Total                                                                                                                                          | <u>1,615,458.76</u>              | <u>7,424,848.36</u>                                                                  |             |

Reasons should be given for the Company defining the non-recurring gain or loss items with significant amount not set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss along with non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss as recurring gain or loss items.

## 1. KEY FINANCIAL DATA (CONTINUED)

### (B) Non-recurring profit or loss items and amounts (continued)

✓Applicable    ☐Not applicable

*Unit: Yuan    Currency: RMB*

| Items                                                                       | Amounts involved | Reasons                                             |
|-----------------------------------------------------------------------------|------------------|-----------------------------------------------------|
| Additional deduction of value-added tax for advanced manufacturing industry | 195,229.74       | Continuous impact on gains or losses of the Company |
| Government grants related to assets                                         | 2,928,203.18     | Continuous impact on gains or losses of the Company |

### (C) Description of and reasons for the changes in key accounting data and financial indicators

✓Applicable    ☐Not applicable

| Item                                     | Change percentage (%) | Main reason(s)                                                                                                                                                                               |
|------------------------------------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Net cash flows from operating activities | -32.68                | The change in net cash flows from operating activities was mainly attributable to the impact of changes in the timing of bill settlement and a decrease in cash collections from operations. |

## 2. INFORMATION OF SHAREHOLDERS

### (A) Total number of ordinary shareholders, number of preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders

*Unit: Share*

|                                                                          |       |                                                                                                                            |      |
|--------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------|------|
| Total number of ordinary shareholders at the end of the Reporting Period | 7,812 | Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period | None |
|--------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------|------|

## 2. INFORMATION OF SHAREHOLDERS (CONTINUED)

### (A) Total number of ordinary shareholders, number of preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders (excluding lending shares through securities financing)                                                                                                                                                           |                         |                       |                             |                                                       |                                                                                                           |                                  |        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------|-----------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------|--------|
| Name of shareholder                                                                                                                                                                                                                                    | Nature of shareholder   | Number of shares held | Shareholding percentage (%) | Number of shares held subject to trading restrictions | Number of Shares subject to trading restrictions that include lending shares through securities financing | Shares charged, tagged or frozen |        |
|                                                                                                                                                                                                                                                        |                         |                       |                             |                                                       |                                                                                                           | Status of shares                 | Number |
| Shi Chunbao                                                                                                                                                                                                                                            | Domestic natural person | 120,209,043           | 31.34                       | 0                                                     | 0                                                                                                         | None                             | 0      |
| Yue Shujun                                                                                                                                                                                                                                             | Domestic natural person | 95,447,900            | 24.88                       | 0                                                     | 0                                                                                                         | None                             | 0      |
| Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP)<br>(北京磐茂投資管理有限公司－磐茂(上海)投資中心(有限合夥))                                                                                                                          | Others                  | 17,250,000            | 4.50                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP)<br>(北京磐茂投資管理有限公司－磐信(上海)投資中心(有限合夥))                                                                                                                          | Others                  | 2,500,000             | 0.65                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| China Merchants Bank Co., Ltd. – Jinxin Shenzhen Growth Flexible Allocation Hybrid Initiated Securities Investment Fund<br>(招商銀行股份有限公司－金信深圳成長靈活配置混合型發起式證券投資基金)                                                                                         | Others                  | 2,408,883             | 0.63                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Hong Kong Securities Clearing Company Limited                                                                                                                                                                                                          | Others                  | 2,084,434             | 0.54                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Huatai Securities (Shanghai) Asset Management Co., Ltd. – Bank of China – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰證券資管－中國銀行－華泰春立醫療家園1號科創板員工持股集合資產管理計劃) | Others                  | 1,500,782             | 0.39                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Xie Huiming (謝慧明)                                                                                                                                                                                                                                      | Domestic natural person | 1,114,270             | 0.29                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Qian Jiaping (錢佳平)                                                                                                                                                                                                                                     | Domestic natural person | 997,075               | 0.26                        | 0                                                     | 0                                                                                                         | None                             | 0      |
| Basic Endowment Insurance Fund Portfolio 903 (基本養老保險基金九零三組合)                                                                                                                                                                                           | Others                  | 970,903               | 0.25                        | 0                                                     | 0                                                                                                         | None                             | 0      |

## 2. INFORMATION OF SHAREHOLDERS (CONTINUED)

### (A) Total number of ordinary shareholders, number of preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing)                                                                                                                       |                                                                    |                                   |             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------|-------------|
| Name of shareholder                                                                                                                                                                                                                                    | Number of tradable shares held not subject to trading restrictions | Share class and number            |             |
|                                                                                                                                                                                                                                                        |                                                                    | Share class                       | Number      |
| Shi Chunbao                                                                                                                                                                                                                                            | 115,473,043                                                        | RMB – denominated ordinary shares | 115,473,043 |
|                                                                                                                                                                                                                                                        | 4,736,000                                                          | Overseas listed foreign shares    | 4,736,000   |
| Yue Shujun                                                                                                                                                                                                                                             | 95,447,900                                                         | RMB – denominated ordinary shares | 95,447,900  |
| Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP)<br>(北京磐茂投資管理有限公司－磐茂(上海)投資中心(有限合夥))                                                                                                                          | 17,250,000                                                         | RMB – denominated ordinary shares | 17,250,000  |
| Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP)<br>(北京磐茂投資管理有限公司－磐信(上海)投資中心(有限合夥))                                                                                                                          | 2,500,000                                                          | RMB – denominated ordinary shares | 2,500,000   |
| China Merchants Bank Co., Ltd. – Jinxin Shenzhen Growth Flexible Allocation Hybrid Initiated Securities Investment Fund<br>(招商銀行股份有限公司－金信深圳成長靈活配置混合型發起式證券投資基金)                                                                                         | 2,408,883                                                          | RMB – denominated ordinary shares | 2,408,883   |
| Hong Kong Securities Clearing Company Limited                                                                                                                                                                                                          | 2,084,434                                                          | RMB – denominated ordinary shares | 2,084,434   |
| Huatai Securities (Shanghai) Asset Management Co., Ltd. – Bank of China – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰證券資管－中國銀行－華泰春立醫療家園1號科創板員工持股集合資產管理計劃) | 1,500,782                                                          | RMB – denominated ordinary shares | 1,500,782   |
| Xie Huiming (謝慧明)                                                                                                                                                                                                                                      | 1,114,270                                                          | RMB – denominated ordinary shares | 1,114,270   |

## 2. INFORMATION OF SHAREHOLDERS (CONTINUED)

### (A) Total number of ordinary shareholders, number of preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing)                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                   |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|---------|
| Name of shareholder                                                                                                                                                                                               | Number of tradable shares held not subject to trading restrictions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Share class and number            |         |
|                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Share class                       | Number  |
| Qian Jiaping (錢佳平)                                                                                                                                                                                                | 997,075                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | RMB – denominated ordinary shares | 997,075 |
| Basic Endowment Insurance Fund Portfolio 903 (基本養老保險基金九零三組合)                                                                                                                                                      | 970,903                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | RMB – denominated ordinary shares | 970,903 |
| Description of connected relationship or acting in concert of the above shareholders                                                                                                                              | <ol style="list-style-type: none"> <li>As of the date of this announcement, Shi Chunbao and Yue Shujun are couple while Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP) and Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP) belong to the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in concert;</li> <li>The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of the Takeover of Listed Companies (《上市公司收購管理辦法》).</li> </ol> |                                   |         |
| Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any) | Xie Huiming holds 1,114,270 shares of the Company through a margin securities account, holding a total of 1,114,270 shares of the Company; Qian Jiaping holds 2,087 shares of the Company through an ordinary securities account and 994,988 shares of the Company through a margin securities account, holding a total of 997,075 shares of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                   |         |

*Note 1:* As of the end of the Reporting Period, the total number of ordinary shareholders of the Company amounted to 7,812, of which 7,797 holders of A Shares and 15 holders of H Shares;

*Note 2:* The shares of the top 10 shareholders are held in Beijing Chunlizhengda Medical Instruments Co., Ltd.\* Designated Security Account for Repurchase. As of 30 September 2026, the Designated Security Account for Repurchase held 1,376,851 shares, representing a shareholding percentage of 0.36%.

Lending of shares by shareholders involved in the securities financing business holding more than 5% of the shares, top 10 shareholders and top 10 shareholders of tradable shares not subject to trading restrictions

☐ Applicable    ☒ Not applicable

The changes of the top 10 shareholders and the top 10 shareholders of tradable shares not subject to trading restrictions resulted from lending/repayment for securities financing compared with the previous period

☐ Applicable    ☒ Not applicable

### 3. OTHER NOTICE

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

☐ Applicable ☒ Not applicable

### 4. QUARTERLY FINANCIAL STATEMENTS

#### (A) Type of auditor's opinion

☐ Applicable ☒ Not applicable

#### (B) Financial statements

#### **Consolidated balance sheet** *30 September 2026*

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

*Unit: Yuan    Currency: RMB    Type of audit: Unaudited*

| Items                                                     | 30 September 2026 | 31 December 2025 |
|-----------------------------------------------------------|-------------------|------------------|
| <b>Current assets:</b>                                    |                   |                  |
| Monetary funds                                            | 1,424,391,036.96  | 1,409,120,983.52 |
| Settlement reserve                                        |                   |                  |
| Placements with banks and non-bank financial institutions |                   |                  |
| Held-for-trading financial assets                         | 746,830,616.44    | 811,246,684.93   |
| Derivative financial assets                               |                   |                  |
| Notes receivables                                         |                   | 4,253,186.08     |
| Accounts receivable                                       | 252,787,702.09    | 225,456,558.88   |
| Accounts receivable financing                             |                   |                  |
| Prepayment                                                | 6,901,214.77      | 4,851,870.27     |
| Premium receivable                                        |                   |                  |
| Reinsurance premium receivables                           |                   |                  |
| Reserves for reinsurance contract receivables             |                   |                  |
| Other receivables                                         | 1,353,710.37      | 222,608.48       |
| Including: Interests receivable                           |                   |                  |
| Dividends receivable                                      |                   |                  |
| Financial assets purchased under agreements to resell     |                   |                  |
| Inventories                                               | 551,950,023.33    | 535,925,459.39   |
| Including: Data resources                                 |                   |                  |
| Contract assets                                           |                   |                  |
| Assets held-for-sale                                      |                   |                  |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated balance sheet (continued)

30 September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                   | 30 September 2026       | 31 December 2025        |
|-----------------------------------------|-------------------------|-------------------------|
| Non-current assets due within one year  |                         |                         |
| Other current assets                    | 22,996,740.83           | 20,422,698.85           |
| <b>Total current assets</b>             | <b>3,007,211,044.79</b> | <b>3,011,500,050.40</b> |
| <b>Non-current assets:</b>              |                         |                         |
| Loans and advances                      |                         |                         |
| Debt investments                        |                         |                         |
| Other debt investments                  |                         |                         |
| Long-term receivables                   |                         |                         |
| Long-term equity investments            |                         |                         |
| Other investments in equity instruments |                         |                         |
| Other non-current financial assets      |                         |                         |
| Investment property                     |                         |                         |
| Fixed assets                            | 339,076,205.46          | 354,149,308.67          |
| Construction in progress                | 131,294,057.57          | 129,329,592.01          |
| Productive biological assets            |                         |                         |
| Oil & gas assets                        |                         |                         |
| Right-of-use assets                     | 5,115,167.19            | 3,840,500.22            |
| Intangible assets                       | 114,468,183.32          | 119,787,805.08          |
| Including: Data resources               |                         |                         |
| Development expenditures                |                         |                         |
| Including: Data resources               |                         |                         |
| Goodwill                                |                         |                         |
| Long-term prepayments                   |                         |                         |
| Deferred income tax assets              | 29,800,523.50           | 30,336,378.81           |
| Other non-current assets                | 21,666,417.82           | 12,191,225.94           |
| <b>Total non-current assets</b>         | <b>641,420,554.86</b>   | <b>649,634,810.73</b>   |
| <b>Total assets</b>                     | <b>3,648,631,599.65</b> | <b>3,661,134,861.13</b> |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated balance sheet (continued)

30 September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                     | 30 September 2026     | 31 December 2025      |
|-----------------------------------------------------------|-----------------------|-----------------------|
| <b>Current liabilities:</b>                               |                       |                       |
| Short-term borrowings                                     |                       |                       |
| Borrowings from central banks                             |                       |                       |
| Placements from banks and non-bank financial institutions |                       |                       |
| Held-for-trading financial liabilities                    |                       |                       |
| Derivative financial liabilities                          |                       |                       |
| Notes payable                                             |                       |                       |
| Accounts payable                                          | 141,794,479.56        | 160,772,940.21        |
| Advances received                                         |                       |                       |
| Contract liabilities                                      | 71,110,449.90         | 82,166,218.34         |
| Financial assets sold under repurchase agreement          |                       |                       |
| Deposits and placements from peers                        |                       |                       |
| Brokerage for trading securities                          |                       |                       |
| Brokerage for underwriting securities                     |                       |                       |
| Employee remuneration payable                             | 48,763,158.39         | 68,607,725.23         |
| Taxes payable                                             | 20,993,808.91         | 26,060,319.15         |
| Other payables                                            | 103,073,171.72        | 181,961,490.77        |
| Including: Interests payable                              |                       |                       |
| Dividend payable                                          |                       | 80,260,246.29         |
| Handling fee and commission payables                      |                       |                       |
| Reinsurance premium payables                              |                       |                       |
| Liabilities held-for-sale                                 |                       |                       |
| Non-current liabilities due within one year               | 2,393,476.25          | 2,677,095.45          |
| Other current liabilities                                 | 51,151,044.71         | 56,357,165.80         |
| <b>Total current liabilities</b>                          | <b>439,279,589.44</b> | <b>578,602,954.95</b> |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated balance sheet (continued)

30 September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                   | 30 September 2026     | 31 December 2025      |
|-----------------------------------------|-----------------------|-----------------------|
| <b>Non-current liabilities:</b>         |                       |                       |
| Reserves for insurance contracts        |                       |                       |
| Long-term borrowings                    |                       |                       |
| Bonds payable                           |                       |                       |
| Including: Preferred shares             |                       |                       |
| Perpetual bonds                         |                       |                       |
| Lease liabilities                       | —                     | 598,047.04            |
| Long-term payables                      |                       |                       |
| Long-term employee remuneration payable |                       |                       |
| Estimated liabilities                   |                       |                       |
| Deferred income                         | 79,566,735.00         | 82,494,938.18         |
| Deferred income tax liabilities         | 11,537,724.67         | 12,446,459.51         |
| Other non-current liabilities           |                       |                       |
|                                         | <hr/>                 | <hr/>                 |
| <b>Total non-current liabilities</b>    | <b>91,104,459.67</b>  | <b>95,539,444.73</b>  |
|                                         | <hr/>                 | <hr/>                 |
| <b>Total liabilities</b>                | <b>530,384,049.11</b> | <b>674,142,399.68</b> |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated balance sheet (continued)

30 September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                              | 30 September 2026                                   | 31 December 2025                                             |
|----------------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|
| <b>Owners' equity (or shareholders' equity):</b>                                                   |                                                     |                                                              |
| Paid-in capital (or share capital)                                                                 | 383,568,500.00                                      | 383,568,500.00                                               |
| Other equity instruments                                                                           |                                                     |                                                              |
| Including: Preferred shares                                                                        |                                                     |                                                              |
| Perpetual bonds                                                                                    |                                                     |                                                              |
| Capital reserve                                                                                    | 1,044,799,419.83                                    | 1,044,799,419.83                                             |
| Less: Treasury shares                                                                              | 20,008,021.82                                       | 20,008,021.82                                                |
| Other comprehensive income                                                                         |                                                     |                                                              |
| Specific reserve                                                                                   |                                                     |                                                              |
| Surplus reserve                                                                                    | 225,066,727.32                                      | 225,066,727.32                                               |
| General reserve                                                                                    |                                                     |                                                              |
| Undistributed profit                                                                               | <u>1,483,269,989.46</u>                             | <u>1,352,041,210.82</u>                                      |
| Total equity attributable to owners (or equity attributable to shareholders) of the parent company | 3,116,696,614.79                                    | 2,985,467,836.15                                             |
| Minority interest                                                                                  | <u>1,550,935.75</u>                                 | <u>1,524,625.30</u>                                          |
| <b>Total owners' equity (or shareholders' equity)</b>                                              | <u><b>3,118,247,550.54</b></u>                      | <u><b>2,986,992,461.45</b></u>                               |
| <b>Total liabilities and owners' equity (or shareholders' equity)</b>                              | <u><b>3,648,631,599.65</b></u>                      | <u><b>3,661,134,861.13</b></u>                               |
| Person in charge of the Company:<br>Shi Wenling                                                    | Person in charge for accounting work:<br>Lu Hongyue | Person in charge of the accounting department:<br>Lu Hongyue |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated income statement

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                   | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|---------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| <b>1. Total operating revenue</b>                       | <b>626,477,112.40</b>                                        | <b>756,093,897.40</b>                                        |
| Including: Operating revenue                            | 626,477,112.40                                               | 756,093,897.40                                               |
| Interest income                                         |                                                              |                                                              |
| Premiums gained                                         |                                                              |                                                              |
| Income from handling fee and<br>commission              |                                                              |                                                              |
| <b>2. Total operating cost</b>                          | <b>419,617,724.72</b>                                        | <b>515,865,735.32</b>                                        |
| Including: Operating cost                               | 222,828,388.90                                               | 247,450,780.09                                               |
| Interest expense                                        |                                                              |                                                              |
| Handling fee and commission<br>expense                  |                                                              |                                                              |
| Surrender value                                         |                                                              |                                                              |
| Net amount of compensation payout                       |                                                              |                                                              |
| Net amount of insurance contracts<br>reserves withdrawn |                                                              |                                                              |
| Policy dividend payment                                 |                                                              |                                                              |
| Reinsurance expenses                                    |                                                              |                                                              |
| Taxes and surcharge                                     | 6,143,429.58                                                 | 6,867,479.82                                                 |
| Selling expenses                                        | 91,121,330.81                                                | 146,195,182.01                                               |
| Administrative expenses                                 | 29,195,566.00                                                | 38,603,081.68                                                |
| Research and development expenses                       | 69,965,203.25                                                | 86,472,598.27                                                |
| Financial expenses                                      | 363,806.18                                                   | -9,723,386.55                                                |
| Including: Interest expenses                            | 76,746.69                                                    | 14,188.80                                                    |
| Interest income                                         | 10,938,382.59                                                | 10,658,846.31                                                |
| Add: Other gains                                        | 5,489,386.04                                                 | 6,909,455.54                                                 |
| Investment income<br>(losses are presented as “-”)      | 2,818,027.41                                                 | 3,217,026.86                                                 |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated income statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                         | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|-------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Including: Investment income from<br>associates and joint ventures            |                                                              |                                                              |
| Gains from derecognition of<br>financial assets measured at<br>amortized cost |                                                              |                                                              |
| Foreign exchange gains<br>(losses are presented as “-”)                       |                                                              |                                                              |
| Net profit on hedging exposure<br>(losses are presented as “-”)               |                                                              |                                                              |
| Gains on changes of fair value<br>(losses are presented as “-”)               | 5,414,835.61                                                 | 7,078,936.97                                                 |
| Loss on credit impairment<br>(losses are presented as “-”)                    | 329,524.06                                                   | -13,646,674.50                                               |
| Loss on asset impairment<br>(losses are presented as “-”)                     | -6,747,349.12                                                | -32,062,823.41                                               |
| Gains on disposal of assets<br>(losses are presented as “-”)                  |                                                              | 3,848.03                                                     |
| <b>3. Operating profit (losses are presented as “-”)</b>                      | <b>214,163,811.68</b>                                        | <b>211,727,931.57</b>                                        |
| Add: Non-operating income                                                     | 160,577.68                                                   | 195,880.52                                                   |
| Less: Non-operating expenses                                                  | 1,837,556.15                                                 | 135,115.14                                                   |
| <b>4. Gross profit (total losses are presented as “-”)</b>                    | <b>212,486,833.21</b>                                        | <b>211,788,696.95</b>                                        |
| Less: Income tax expenses                                                     | 23,902,996.77                                                | 20,176,273.09                                                |
| <b>5. Net profit (net losses are presented as “-”)</b>                        | <b>188,583,836.44</b>                                        | <b>191,612,423.86</b>                                        |
| (I) Classified by continuity of operation                                     |                                                              |                                                              |
| 1. Net profit for continuing operation (net<br>losses are presented as “-”)   | 188,583,836.44                                               | 191,612,423.86                                               |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

###### Consolidated income statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                                  | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| 2. Net profit for ceased operation (net losses are presented as “-”)                                   |                                                              |                                                              |
| (II) Classified by ownership                                                                           |                                                              |                                                              |
| 1. Net profit attributable to the shareholders of the parent company (net losses are presented as “-”) | 188,557,525.99                                               | 191,531,404.47                                               |
| 2. Non-controlling shareholders’ profit or loss (net losses are presented as “-”)                      | 26,310.45                                                    | 81,019.39                                                    |

#### 6. Net other comprehensive income after tax

- (I) Net other comprehensive income after tax attributable to owners of the parent company
  - 1. Other comprehensive income that cannot be reclassified into profit or loss
    - (1) Changes in remeasurement on defined benefit plan
    - (2) Other comprehensive income that cannot be transferred to profit and loss under equity method
    - (3) Fair value change on other investments in equity instruments
    - (4) Fair value change on credit risk of the enterprise
    - (5) Others
  - 2. Other comprehensive income that will be reclassified into profit or loss
    - (1) Other comprehensive income that can be transferred to profit and loss under equity method
    - (2) Fair value change on other debt investments

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated income statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                      | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| (3) Amounts of financial assets<br>reclassified into other<br>comprehensive income         |                                                              |                                                              |
| (4) Provision on credit impairment on<br>other debt investments                            |                                                              |                                                              |
| (5) Reserves of cash flow hedging                                                          |                                                              |                                                              |
| (6) Translation difference on financial<br>statements denominated in foreign<br>currencies |                                                              |                                                              |
| (7) Others                                                                                 |                                                              |                                                              |
| (II) Net other comprehensive income after tax<br>attributable to minority shareholders     |                                                              |                                                              |
| <b>7. Total comprehensive income</b>                                                       | <b>188,583,836.44</b>                                        | <b>191,612,423.86</b>                                        |
| (I) Total comprehensive income attributable to<br>the owners of the parent company         | 188,557,525.99                                               | 191,531,404.47                                               |
| (II) Total comprehensive income attributable to<br>minority shareholders                   | 26,310.45                                                    | 81,019.39                                                    |
| <b>8. Earnings per share:</b>                                                              |                                                              |                                                              |
| (I) Basic earnings per share (RMB/share)                                                   | 0.49                                                         | 0.50                                                         |
| (II) Diluted earnings per share (RMB/share)                                                | 0.49                                                         | 0.50                                                         |

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

Person in charge of the  
Company:  
Shi Wenling

Person in charge for  
accounting work:  
Lu Hongyue

Person in charge of the  
accounting department:  
Lu Hongyue

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated cash flow statement January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

*Unit: Yuan    Currency: RMB    Type of audit: Unaudited*

| Items                                                                            | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|----------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| <b>1. Cash flows from operating activities:</b>                                  |                                                              |                                                              |
| Cash receipts from sale of goods and rendering of services                       | 587,450,402.07                                               | 787,304,954.60                                               |
| Net increase in the amounts of deposits from customers and placements from peers |                                                              |                                                              |
| Net increase in amounts due to central banks                                     |                                                              |                                                              |
| Net increase in placements from other financial institutions                     |                                                              |                                                              |
| Cash received from the premium of original insurance contract                    |                                                              |                                                              |
| Net cash received from reinsurance business                                      |                                                              |                                                              |
| Net increase in policyholder deposits and amount for investment                  |                                                              |                                                              |
| Cash received from interest, handling fee and commission                         |                                                              |                                                              |
| Net increase in placements from banks and non-bank financial institutions        |                                                              |                                                              |
| Net increase in capital on business repurchased                                  |                                                              |                                                              |
| Net cash received on securities dealing agency services                          |                                                              |                                                              |
| Receipts of tax refund                                                           | 846,367.28                                                   | 2,825,763.95                                                 |
| Other cash receipts related to operating activities                              | 22,740,576.07                                                | 15,765,417.63                                                |
| Subtotal of cash inflow from operating activities                                | <u>611,037,345.42</u>                                        | <u>805,896,136.18</u>                                        |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated cash flow statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                             | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Cash payments for goods purchased and services received                                           | 182,786,432.33                                               | 298,567,305.53                                               |
| Net increase in loans and advances from customers                                                 |                                                              |                                                              |
| Net increase in amounts deposited in central bank and peers                                       |                                                              |                                                              |
| Cash payment on compensation payout in original insurance contract                                |                                                              |                                                              |
| Net increase in placements with banks and non-bank financial institutions                         |                                                              |                                                              |
| Cash payment on interest, handling fee and commission                                             |                                                              |                                                              |
| Cash payment for policy dividend                                                                  |                                                              |                                                              |
| Cash paid to and on behalf of employees                                                           | 136,014,227.83                                               | 149,971,256.13                                               |
| Taxes paid                                                                                        | 53,431,764.34                                                | 29,932,778.50                                                |
| Other cash payments related to operating activities                                               | 121,290,508.37                                               | 152,857,751.91                                               |
| Subtotal of cash outflow from operating activities                                                | 493,522,932.87                                               | 631,329,092.07                                               |
| Net cash flow from operating activities                                                           | 117,514,412.55                                               | 174,567,044.11                                               |
| <b>2. Cash flows from investing activities:</b>                                                   |                                                              |                                                              |
| Cash received from disinvestments                                                                 | 790,000,000.00                                               | 744,000,000.00                                               |
| Cash received from return on investments                                                          | 7,648,931.51                                                 | 6,619,109.04                                                 |
| Net cash received from the disposal of fixed assets, intangible assets and other long-term assets | 87,000.00                                                    | 23,000.00                                                    |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated cash flow statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                 | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September) |
|---------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Net cash received from the disposal of<br>subsidiaries and other business units       |                                                              |                                                              |
| Other cash receipts related to investing activities                                   |                                                              |                                                              |
| Subtotal of cash inflow from investing activities                                     | 797,735,931.51                                               | 750,642,109.04                                               |
| Cash paid for acquiring fixed assets, intangible<br>assets and other long-term assets | 31,522,559.67                                                | 48,492,401.83                                                |
| Cash payments for investments                                                         | 725,000,000.00                                               | 880,000,000.00                                               |
| Net increase in pledged loans                                                         |                                                              |                                                              |
| Net cash payments for acquisition of<br>subsidiaries and other business units         |                                                              | 2,200,000.00                                                 |
| Other cash payments related to financing<br>activities                                |                                                              |                                                              |
| Subtotal of cash outflow from investing<br>activities                                 | 756,522,559.67                                               | 930,692,401.83                                               |
| Net cash flows from investing activities                                              | 41,213,371.84                                                | -180,050,292.79                                              |
| <b>3. Cash flows from financing activities:</b>                                       |                                                              |                                                              |
| Cash received from investments                                                        |                                                              |                                                              |
| Including: Cash received by subsidiaries from<br>minority shareholders' investments   |                                                              |                                                              |
| Cash received from borrowings                                                         |                                                              |                                                              |
| Other cash receipts related to financing<br>activities                                |                                                              |                                                              |
| Subtotal of cash inflow from financing activities                                     |                                                              |                                                              |

#### 4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

##### (B) Financial statements (continued)

##### Consolidated cash flow statement (continued)

January to September 2026

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan    Currency: RMB    Type of audit: Unaudited

| Items                                                                                                         | First three<br>quarters of 2026<br>(January to<br>September) | First three<br>quarters of 2025<br>(January to<br>September)    |
|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------|
| Cash repayment of debts                                                                                       |                                                              |                                                                 |
| Cash paid for distribution of dividends, profits<br>or for interest expenses                                  | 137,588,993.64                                               | 18,727,390.80                                                   |
| Including: Cash paid for distribution of<br>dividends and profits by subsidiaries to<br>minority shareholders |                                                              |                                                                 |
| Other cash payments related to financing<br>activities                                                        | 5,112,942.36                                                 | 8,656,570.63                                                    |
| Subtotal of cash outflow from financing<br>activities                                                         | 142,701,936.00                                               | 27,383,961.43                                                   |
| Net cash flows from financing activities                                                                      | -142,701,936.00                                              | -27,383,961.43                                                  |
| <b>4.Effect of foreign exchange rate changes on cash<br/>and cash equivalents</b>                             | -563,101.66                                                  | -248,760.77                                                     |
| <b>5.Net increase in cash and cash equivalents</b>                                                            | 15,462,746.73                                                | -33,115,970.88                                                  |
| Add: Opening balance of cash and cash<br>equivalents                                                          | 1,402,472,486.98                                             | 1,139,017,650.66                                                |
| <b>6.Closing balance of cash and cash equivalents</b>                                                         | 1,417,935,233.71                                             | 1,105,901,679.78                                                |
| Person in charge of the<br>Company:<br>Shi Wenling                                                            | Person in charge for<br>accounting work:<br>Lu Hongyue       | Person in charge of the<br>accounting department:<br>Lu Hongyue |

**(C) Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2026**

☐ Applicable    ☒ Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.\*  
30 October 2026

\* *For identification purposes only*